Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions by Aziz, Athar et al.
Cooperativity of imprinted genes inactivated by acquired chromosome
20q deletions
Aziz, A., Baxter, E. J., Edwards, C., Cheong, C. Y., Ito, M., Bench, A., ... Green, A. R. (2013). Cooperativity of
imprinted genes inactivated by acquired chromosome 20q deletions. The Journal of clinical investigation, 123(5),
2169-2182. DOI: 10.1172/JCI66113
Published in:
The Journal of clinical investigation
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright © 2017 American Society for Clinical Investigation. This work is made available online in accordance with the publisher’s policies.
Please refer to any applicable terms of use of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:06. Nov. 2017
Research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 5   May 2013 2169
Cooperativity of imprinted genes inactivated 
by acquired chromosome 20q deletions
Athar Aziz,1,2 E. Joanna Baxter,1,2,3 Carol Edwards,4 Clara Yujing Cheong,5 Mitsuteru Ito,4  
Anthony Bench,3 Rebecca Kelley,1,2 Yvonne Silber,1,2 Philip A. Beer,1,2,3 Keefe Chng,5  
Marilyn B. Renfree,6 Kirsten McEwen,4 Dionne Gray,4 Jyoti Nangalia,1,2,3 Ghulam J. Mufti,7  
Eva Hellstrom-Lindberg,8 Jean-Jacques Kiladjian,9,10 Mary Frances McMullin,11  
Peter J. Campbell,2,3,12 Anne C. Ferguson-Smith,4 and Anthony R. Green1,2,3
1Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute and 2Department of Hematology,  
University of Cambridge, Cambridge, United Kingdom. 3Department of Hematology, Addenbrooke’s Hospital, Cambridge, United Kingdom.  
4Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, United Kingdom.  
5A*STAR Singapore Institute for Clinical Sciences, Brenner Centre for Molecular Medicine, Singapore. 6Department of Zoology,  
University of Melbourne, Melbourne, Victoria, Australia. 7Department of Hematological Medicine, King’s College London, London, United Kingdom.  
8Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.  
9Hopital Saint-Louis, AP-HP, Centre d’Investigations Cliniques, Paris, France. 10Université Paris 7 Denis Diderot, Paris, France.  
11Center for Cancer Research and Cell Biology, Queen’s University, Belfast, United Kingdom.  
12Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom.
Large regions of recurrent genomic loss are common in cancers; however, with a few well-characterized 
exceptions, how they contribute to tumor pathogenesis remains largely obscure. Here we identified primate-
restricted imprinting of a gene cluster on chromosome 20 in the region commonly deleted in chronic myeloid 
malignancies. We showed that a single heterozygous 20q deletion consistently resulted in the complete loss of 
expression of the imprinted genes L3MBTL1 and SGK2, indicative of a pathogenetic role for loss of the active 
paternally inherited locus. Concomitant loss of both L3MBTL1 and SGK2 dysregulated erythropoiesis and 
megakaryopoiesis, 2 lineages commonly affected in chronic myeloid malignancies, with distinct consequences 
in each lineage. We demonstrated that L3MBTL1 and SGK2 collaborated in the transcriptional regulation of 
MYC by influencing different aspects of chromatin structure. L3MBTL1 is known to regulate nucleosomal 
compaction, and we here showed that SGK2 inactivated BRG1, a key ATP-dependent helicase within the SWI/
SNF complex that regulates nucleosomal positioning. These results demonstrate a link between an imprint-
ed gene cluster and malignancy, reveal a new pathogenetic mechanism associated with acquired regions of 
genomic loss, and underline the complex molecular and cellular consequences of “simple” cancer-associated 
chromosome deletions.
Introduction
Many human malignancies harbor large-scale regions of genetic 
loss that may be evident as monosomy, interstitial deletion, or 
acquired uniparental disomy (UPD), with particular changes 
often recurrent in specific tumor types (1, 2). UPD may be associ-
ated with gain-of-function mutations that become homozygous 
following mitotic recombination (e.g., JAK2V617F, refs. 3–6). Some 
chromosomal deletions mark the site of a tumor suppressor gene 
that is inactivated on the normal chromosome (e.g., RB and TP53), 
whereas others are thought to reflect haploinsufficiency of at least 
1 target gene (7–9). However, in most cases, our understanding of 
the underlying mechanisms is incomplete or absent.
Chronic myeloid malignancies are associated with deletions of 
20q (10–12). The 20q minimal deleted region spans 1.9 Mb and 
contains multiple genes, including L3MBTL1 (13), a transcrip-
tional repressor (14–16) homologous to the Drosophila tumor-sup-
pressor gene lethal(3) malignant brain tumor (17, 18). L3MBTL1 
binds to mono- and dimethyl lysine residues through its MBT 
repeats (19, 20), and creates a compacted chromatin structure (16, 
21). Its biological functions are largely unclear, but it is reported 
to repress E2F target genes (16), inhibit RUNX1 expression (15), 
and modulate DNA replication and repair (22). Knockdown and 
overexpression studies in primary CD34+ cells and in hematopoi-
etic cell lines have indicated that L3MBTL1 restricts erythroid dif-
ferentiation (22). However, acquired mutations in L3MBTL1 have 
not been found in primary cells from myelodysplastic syndrome 
(MDS) or myeloproliferative neoplasm (MPN) patients with or 
without a 20q deletion (13, 23), and transcript levels of L3MBTL1 
were reported to be unaffected in primary cells from patients with 
a 20q deletion (13).
We have previously demonstrated that L3MBTL1 is imprinted 
in humans, but surprisingly not in mice (Mus musculus) (24, 25). 
Imprinted genes function in the control of prenatal growth, in 
the development of particular organ systems, including the pla-
centa, and in the postnatal control of metabolic and neural pro-
cesses (26, 27). Loss of imprinting has frequently been found in 
cancers and is associated with altered patterns of expression that 
characterize the tumorigenic state (28). Inherited deletions influ-
encing long-range epigenetic control at imprinted loci are associ-
ated with increased tumor incidence, particularly in the context 
of Beckwith-Wiedemann syndrome (29, 30), but imprinted loci 
have not been identified as direct targets of acquired tumor-asso-
ciated genomic changes.
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Results
The 20q common deleted region contains a cluster of genes that exhibit 
primate-restricted imprinting. Having previously shown that one of 
the genes in the 20q common deleted region (CDR), L3MBTL1, is 
imprinted (24), we considered the possibility that other genes in 
the vicinity may also be imprinted and contribute to the pathogen-
esis of malignancies associated with 20q deletions. We therefore 
determined allele-specific expression of neighboring genes in the 
20q CDR (Figure 1A). Most genes (SFRS6, IFT52, MYBB, JPH2, and 
C20orf111) were biallelically expressed in normal peripheral blood 
cells, but SGK2 (encoding a serine/threonine kinase) and GDAP1L1 
(encoding a protein of unknown function) each exhibited monoal-
lelic expression in 2 different hematopoietic cell types (Figure 1B 
and Supplemental Table 1; supplemental material available online 
with this article; doi:10.1172/JCI66113DS1). Studies of 6 fami-
lies showed that, like L3MBTL1, both SGK2 (n = 4) and GDAP1L1 
(n = 2) were expressed from the paternal allele (Figure 1C and Sup-
plemental Figure 1).
To identify candidate imprinting control regions, CpG islands 
and islets within the myeloid CDR (Figure 1A) were identified 
in silico and confirmed by immunoprecipitation of methyl-
ated DNA from normal individuals using an anti-methylcyto-
sine antibody. This approach identified 4 methylated regions 
in the vicinity of L3MBTL1 and SGK2 and 1 in the GDAP1L1 
Figure 1
L3MBTL1, SGK2, and GDAP1L1 
constitute a novel imprinting clus-
ter. (A) 20q12 region, with MPN 
and MDS CDRs and the over-
lapping myeloid CDR, as previ-
ously defined by Bench et al. (13). 
Genes in black are expressed 
in hematopoietic cells; genes in 
white are not. (B) Monoallelic 
expression of L3MBTL1, SGK2, 
and GDAP1L1 in hematopoietic 
cells. Grans, granulocytes; gDNA, 
genomic DNA. (C) Family stud-
ies demonstrated that SGK2 and 
GDAP1L1 were expressed from 
the paternally derived allele in T 
cells and erythroblasts, respec-
tively. The respective cell types 
were chosen because they 
express readily detectable lev-
els of SGK2 and GDAP1L1. The 
expressed allele is indicated by 
an arrowhead. See Supplemental 
Figure 1 for other families. 
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promoter (Figure 2A and data not shown). Cloning and sequenc-
ing of bisulphite-treated granulocyte DNA demonstrated that 
only the L3MBTL1 promoter 2 region had the characteristics of a 
parental origin–specific differentially methylated region (DMR), 
with both methylated and unmethylated clones obtained from 
peripheral blood granulocytes, but only unmethylated clones 
from sperm (Figure 2A). L3MBTL1 promoter 2 was also unmeth-
ylated in sperm of a nonhuman primate, the long-tailed macaque 
(Macaca fascicularis), but was methylated in macaque primordial 
follicles and oocytes (Figure 2B). Moreover, in macaque muscle, 
the methylated allele segregated with the T allele of a nearby SNP 
(Figure 2B). These data demonstrate that the L3MBTL1 promoter 
2 region contains a germline DMR in primates that acquires its 
methylation in the female germline and represents a candidate 
imprinting control region.
The evolution of this previously unrecognized cluster of 
imprinted genes was assessed by studying their expression 
in mice, macaques, and tammar wallabies (Macropus eugenii). 
L3mbtl1 is not imprinted in mice (25); similarly, both Sgk2 and 
Gdap1l1 were biallelically expressed in multiple murine tissues 
(Supplemental Figure 2A). Likewise, the tammar wallaby L3MB-
TL1 gene was biallelically expressed in several tissues analyzed 
from 4 informative individuals (Supplemental Figure 2B). Bial-
lelic expression of L3MBTL was also confirmed in a second mar-
supial, the opossum (data not shown). In metatherians, such as 
tammar wallabies and opossums, the cluster organization was 
not conserved, and SGK2 was not linked to L3MBTL. In macaque 
liver and kidney, L3MBTL1 and SGK2 expression were monoal-
lelic and biallelic, respectively, in all 4 informative animals 
studied, and in whole blood, L3MBTL1 and SGK2 were monoal-
lelically expressed in 2 of 4 animals (Supplemental Figure 2C), 
observations reminiscent of tissue-specific and polymorphic 
imprinting (31–33). Expression of GDAP1L1 was not detectable 
in the macaque tissues analyzed. Together, these results revealed 
the existence of a previously unrecognized imprinted gene clus-
ter and suggest that the imprinting arose less than 92 million 
years ago in the primate line after its divergence from other pla-
cental mammals (Supplemental Figure 2D).
Figure 2
Characterization of the L3MB-
TL1 germline DMR in primates. 
(A) L3MBTL1 and SGK2 locus, 
indicating the positions of the 
methylated regions identi-
fied by in silico analysis (red 
bars) and methylated DNA 
immunoprecipitation from normal 
human sperm and granulocytes. 
The DMR in L3MBTL1 promoter 
2 is indicated. Each line repre-
sents a unique bisulphite-treated 
PCR product. Methylated and 
unmethylated CpGs are repre-
sented by filled and unfilled cir-
cles, respectively. (B) L3MBTL1 
promoter 2 is a germline DMR 
in primates. Sequence analysis 
of bisulphite-treated DNA from 
macaque cells. Methylated and 
unmethylated CpGs are repre-
sented by filled and open circles, 
respectively. M1 and M2, males 
1 and 2; GV, germinal vesicle; 
MII, meiosis II. The allele for 
a C/T SNP is indicated for the 
muscle data.
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Loss of expression of imprinted genes in neoplastic myeloid cells harbor-
ing a 20q deletion. The imprinted gene cluster is located within the 
region of 20q deleted in myeloid malignancies (11–13, 23), but lev-
els of L3MBTL1 transcripts were reported to be similar in cells from 
patients with and without a 20q deletion (13). However, interpre-
tation of these results is complicated by several issues: (a) the fact 
that the presence of even a small fraction of nondeleted cells in 
patient samples would mask loss of expression in those carrying 
the 20q deletion; (b) the presence of an antisense transcript, which 
was detectable by the primers used by Bench et al. (13) and extend-
Figure 3
Expression of imprinted genes is lost in hematopoietic cells carrying the 20q deletion. (A) RT-PCR analysis of the full-length (exon 9–14) 
and short (exons 13a–14) isoforms of L3MBTL1 using cell line cDNAs as indicated. (B) RT-PCR analysis of SGK2, GDAP1L1, MYBB, 
and ACTB using cell line cDNAs as in A. Copy number of the 20q region (CN) was determined by FISH. (C) qPCR analysis of granulocyte 
cDNAs in normal (N) patients, patients with 20q deletion [Del(20q)], and PV patients without 20q deletion. (D) qPCR analysis of BM from 
normal patients and from patients with 20q deletion, purified CD34+ cells, and 20q deletion cell lines. In C and D, primers for qPCR of 
L3MBTL1 were in exon 10 and exon 11.
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ed into the 3′ exons of L3MBTL1 (Supplemental Figure 3, A and B); 
(c) the demonstration that the L3MBTL1 locus was transcription-
ally complex with truncated and alternatively spliced transcripts 
(Supplemental Figure 3A).
In order to circumvent the issue of contaminating nondeleted 
cells, we studied 2 hematopoietic cell lines (UKE-1 and HNT-34) 
that carry a cytogenetically detectable 20q deletion, the presence 
of which was confirmed by FISH (data not shown). Using 5′ prim-
ers that do not detect the antisense transcript, we found that 
L3MBTL1 transcripts were undetectable in both 20q deleted cell 
lines, but were readily apparent in 4 other myeloid cell lines (Figure 
3A). Strand-specific RT-PCR showed that both the sense and the 
antisense transcripts were expressed from the same parental allele 
(Supplemental Figure 3C), which indicates that the antisense tran-
script does not function in cis to silence L3MBTL1 expression. The 
antisense transcript was detectable in HNT-34 cells using nonquan-
titative RT-PCR (Supplemental Figure 3B). However, quantitative 
RT-PCR (qPCR) demonstrated that, compared with normal cells, 
the level of the antisense transcript was ∼10 fold lower in cells car-
rying a 20q deletion (Supplemental Figure 3D), likely representing 
very-low-level transcription from the repressed allele, as previously 
reported for other imprinted loci (34, 35). This very-low-level tran-
scription could account, at least in part, for the apparent expression 
of L3MBTL1 in 20q deletion patients reported previously (13). All 
3 L3MBTL1 transcripts were lost in the 2 cell lines carrying a 20q 
deletion (Figure 3A), which demonstrated that differential imprint-
ing of individual transcripts did not occur, at least in these cells. 
Moreover, SGK2 and GDAP1L1 transcripts were also undetectable 
(Figure 3B). Together, these results raised the possibility that loss of 
expression of 1 or more of the 3 imprinted genes (L3MBTL1, SGK2, 
and GDAP1L1) contributes to the pathogenesis of hematological 
malignancies associated with 20q deletions.
Expression of genes located within the 20q CDR was then 
assessed in peripheral blood granulocytes or BM from patients 
with a myeloid malignancy carrying a 20q deletion, from cytoge-
netically normal patients with polycythemia vera (PV), and from 
hematologically normal individuals. Since even a small number 
of contaminating nondeleted cells would mask loss of expression, 
microsatellite PCR was used to quantify the proportion of cells 
carrying a 20q deletion (Supplemental Figure 3E), and subsequent 
analysis was restricted to 6 patients in whom the 20q deletion was 
present in greater than 98% of cells (patients 1–6; Supplemental 
Table 2). qPCR demonstrated that transcripts for L3MBTL1, SGK2, 
and GDAP1L1 were extremely low or undetectable in peripheral 
blood granulocytes or BM from all 6 patients with a 20q deletion, 
but were readily detectable in all normal individuals and cyto-
genetically normal PV patients (Figure 3, C and D). In contrast, 
transcript levels of nonimprinted genes located in the 20q CDR 
(SFRS6, IFT52, and MYBB) were readily evident in 20q deletion 
patient samples and cell lines (Figure 3, C and D). A prior report 
that SGK2 and JPH2 were not expressed in normal BM or BM-
derived CD34+ cells used a less sensitive RT-PCR (13). All qPCR 
data were normalized to ABL, which has previously been shown to 
be the most consistently expressed control gene in hematopoietic 
cells (36). Since loss of expression might arise through somatic 
mutation, we sequenced all known promoters, exons, and splice 
sites for L3MBTL1, SGK2, and GDAP1L1. Several SNPs were iden-
tified (Supplemental Table 3), but no somatic mutations were 
detected, in samples from 23 patients with a 20q deletion (15 MPN 
and 8 MDS) or from 19 cytogenetically normal PV patients.
In order to extend the dataset further, clonal analysis of individ-
ual hematopoietic colonies was performed using samples from an 
additional 8 patients in whom the deletion was present in a smaller 
percentage of cells (<95%; patients 7–14; Supplemental Table 2, Fig-
ure 4, A–D, and Supplemental Figure 4, B–H). Colonies were grown 
from CD34+ cells to minimize contamination by background non-
deleted cells, and each colony was assessed for the presence of the 
20q deletion using several informative markers to ensure accu-
rate genotyping and circumvent apparent loss of heterozygosity 
(LOH) resulting from preferential amplification of smaller alleles 
(Supplemental Figure 4A). All colonies (GM-CFUs and erythroid 
burst-forming units [E-BFUs]) carrying the 20q deletion expressed 
normal levels of MYBB, C20orf111, and IFT52 transcripts, but — in 
marked contrast — lacked detectable levels of L3MBTL1 transcripts 
(Figure 4, A–D, and Supplemental Figure 4, B–H). The variation in 
expression levels in normal colonies is likely to reflect differences in 
cellular composition and maturity of individual colonies. Analysis 
of SGK2 was precluded by low levels of expression in normal colo-
nies, and GDAP1L1 expression was undetectable in some, but not 
all, colonies carrying the 20q deletion (Figure 4 and Supplemen-
tal Figure 4, B–H). Interestingly, in patient 14, myeloid colonies 
expressed GDAP1L1, but erythroid colonies did not (Supplemen-
tal Figure 4, G and H), which suggests that control of GDAP1L1 
imprinting on the retained allele is subject to tighter regulation in 
the erythroid lineage than the myeloid lineage. The variable loss of 
GDAP1L1 expression may reflect the fact that GDAP1L1 is locat-
ed greater than 800 kb from the germline DMR identified above; 
relaxed control of monoallelic expression by an imprinting control 
region has previously been reported for genes at this distance from 
the controlling element (37, 38). Alternatively, the GDAP1L1 locus 
may be subject to a distinct imprinting mechanism from that regu-
lating the L3MBTL1 and SGK2 genes.
In total, we showed loss of L3MBTL1 expression in all 16 sam-
ples (14 patients and 2 cell lines) from individuals with a 20q dele-
tion, which suggests that the paternal allele is consistently lost. 
MPN patients are elderly, and so parental samples are not avail-
able to confirm this; however, it is possible to infer the parental 
origin of the retained L3MBTL1 allele by assessing the methyla-
tion status of its DMR. Of the 6 patients studied here, in whom 
the 20q deletion was present in the majority of granulocytes and 
L3MBTL1 expression was lost, the retained L3MBTL1 allele was pre-
viously shown to be methylated in 5 patients, but unmethylated 
in 1 (24). These results were confirmed using quantitative pyrose-
quencing (39) for all 5 patients for whom samples were available, 
including the one with an unmethylated retained allele (patient 
5; Figure 4E). The discrepancy between expression and methyla-
tion in patient 5 could reflect retention of the maternal allele with 
aberrant hypomethylation, or retention of the paternal allele 
with additional lesions causing loss of expression. To distinguish 
between these possibilities, we investigated the methylation status 
of a second imprinted gene outside the L3MBTL1 cluster, neuro-
natin (NNAT, ref. 40). NNAT is known to be expressed from its 
paternal allele, methylated at the maternally inherited promoter, 
and located within the boundaries of most 20q deletions. Patient 
samples lacking a 20q deletion showed that, as expected, approxi-
mately 50% of CpG dinucleotides were methylated. In contrast, 
all patient samples with a 20q deletion (including patient 5) had 
hypermethylation at the NNAT DMR (Figure 4E). These data indi-
cate that the maternally derived chromosome 20 was retained in 
all patients studied and that in patient 5, the retained L3MBTL1 
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allele was aberrantly hypomethylated. Taken together, our data 
demonstrated that myeloid malignancies carrying a 20q dele-
tion harbor markedly reduced levels of L3MBTL1, SGK2, and/or 
GDAP1L1 transcripts and indicate that loss of the active paternally 
inherited locus likely provides a selective advantage.
L3MBTL1 and SGK2 cooperate to regulate hematopoiesis: coordinated 
silencing maintains megakaryopoiesis and enhances erythropoiesis, but does 
not provide a selective advantage to stem and early progenitor cells. Hyper-
cellular BM with increased erythropoiesis and aberrant mega-
karyopoieis are features shared by many MDS and MPN patients. 
Figure 4
Loss of expression of imprinted genes in hematopoietic colonies carrying a chromosome 20q deletion. (A–D) Expression of imprinted genes 
in E-BFUs (E) and GM-CFUs (GM) from a normal individual (A) and in hematopoietic colonies from patients 7, 10, and 11 (B–D; Supplemental 
Table 2). Each data point represents the mean of 2 qPCR technical replicates. (B) For patient 7, GM-CFUs were analyzed, and all colonies carried 
the 20q deletion. (C) For patient 10, E-BFUs were analyzed with or without the 20q deletion. (D) For patient 11, E-BFUs were analyzed, and all 
colonies carried the 20q deletion. See Supplemental Figure 4 for further patient sample analyses. (E) Quantitative pyrosequencing of NNAT DMR 
(chr20:36148604–36150136) and L3MBTL1 DMR (chr20:42143211–42143591) in normal granulocyte bisulphite-treated DNA (Gr1 and Gr2), BM 
from an MDS patient with cytogenetically normal 20q bisulphite-treated DNA (BM), and the indicated patients with 20q deletion. Each data point rep-
resents percent methylation detected at a single CpG dinucleotide (CpG1–CpG9 on x axis); each pyrosequencing PCR was performed in triplicate.
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To investigate a pathogenetic role for the imprinted cluster on 20q, 
we examined the function of L3MBTL1 and SGK2 in the erythroid 
and megakaryocytic lineages. Transcript levels of both genes were 
modulated during erythroid and megakaryocytic differentiation 
of normal CD34+ progenitors and were repressed by 2 independent 
lentiviral shRNAs for each gene (Supplemental Figure 5, A and B). 
Inhibition of L3MBTL1 during the differentiation of CD34+ cells 
did not alter the generation of erythroid (CD71+GPA+) or mega-
karyocytic (CD41+CD61+) cells, whereas SGK2 inhibition signifi-
cantly reduced megakaryocytic cell formation (Figure 5, A and B). 
Combined knockdown of both L3MBTL1 and SGK2 reversed the 
inhibitory effect of knocking down SGK2 alone (Figure 5B), which 
indicates that loss of L3MBTL1 is able to compensate for loss of 
SGK2 and maintain megakaryopoiesis.
In this monophasic culture system, we noted that the percent-
age of GFP+ cells expressing erythroid or megakaryocytic markers 
was already increased at day 4 after introduction of shRNAs to 
L3MBTL1 or SGK2 (Figure 5C and Supplemental Figure 5, C–E), 
suggestive of an early effect during differentiation. To investigate 
this possibility, we used a biphasic culture (Figure 6A and Supple-
mental Figure 6A), in the first phase of which CD71+GPA+/– early 
erythroid cells are generated, but their subsequent differentiation 
is blocked. In the second phase, the culture conditions are altered 
to allow differentiation into CD71–GPA+ late erythroid cells. Late 
erythroid differentiation was not affected by repressing L3MBTL1 
and/or SGK2 (Figure 6B). In contrast, repression of either L3MB-
TL1 or SGK2 alone significantly increased the number of CD71+ 
early erythroblasts and the percentage of these cells in S phase, 
without any alteration in apoptosis (Figure 6B and Supplemental 
Figure 6, B and C). Inhibition of both genes resulted in an even 
more marked increase in the number of early erythroblasts and 
in the percentage of cells in S phase (Figure 6B and Supplemental 
Figure 6B), which demonstrated a cooperative effect on the prolif-
eration of early erythroid progenitors.
These results predicted that expression of L3MBTL1 and/or 
SGK2 in cells carrying a 20q deletion would inhibit erythroid 
differentiation. To investigate this possibility, L3MBTL1 and/
or SGK2 was expressed in HNT-34 cells (which carry a 20q dele-
tion) derived from a patient with MDS (Supplemental Figure 6D). 
Hemin-induced expression of GPA, α-globin, and β-globin was 
suppressed by introduction of L3MBTL1 or SGK2, with expression 
of both producing significantly more repression of GPA (Figure 
6C and Supplemental Figure 6, E and F). In addition, when HNT-
34 cells were cultured with the demethylating agent 5-azacytidine, 
Figure 5
Silencing of L3MBTL1 and SGK2 promotes erythroid and megakaryocytic differentiation. (A) Single-phase erythroid (Ery; CD71+GPA+) or mega-
karyocytic (Meg; CD41+CD61+) culture of CD34+ cells. LV, lentiviral. (B) In vitro cell counts showing the effect on erythroid or megakaryocytic differen-
tiation upon lentiviral shRNA-mediated knockdown of L3MBTL1 (L3-shRNA1), SGK2 (S2-shRNA1), L3MBTL1 and SGK2 together (L3+S2-shRNA), 
or scrambled control (Scr-shRNA). GFP+, single shRNA-LV; GFP+CFP+, double shRNA-LV. (C) Erythroid and megakaryocytic cells, expressed as a 
percentage of total GFP+ or GFP+CFP+ cells. Error bars indicate SEM of 6 independent experiments. *P < 0.05, **P < 0.01 versus scrambled control. 
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Figure 6
Coordinated silencing of L3MBTL1 and SGK2 increases proliferation of early erythroid progenitors. (A) Biphasic erythroid culture of CD34+ cells. 
(B) In vitro cell count after shRNA-mediated knockdown of L3MBTL1, SGK2, L3MBTL1 and SGK2 together, or scrambled control. Error bars indi-
cate SEM of 5 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 versus scrambled control. (C) Hemin-induced erythroid differentiation 
of HNT-34 cells after retroviral (RV) infection. FACS analysis of hemin-induced GPA expression is also shown, summarized as MFI of GPA in 3 
independent experiments. EV, empty vector. Error bars indicate SEM. ***P < 0.001 versus empty vector. (D) Erythroid differentiation of 20q dele-
tion clones obtained from patient 13. Single-cell clones were grown in erythroid conditions from CD34+ cells retrovirally infected with L3MBTL1, 
SGK2, L3MBTL1 and SGK2 together, or empty vector. Shown are representative 20q deletion clones and MFI of GPA expression in 20q deletion 
clones (n = 39 [empty vector]; 37 [L3MBTL1]; 27 [SGK2]; 21 [L3MBTL1 and SGK2 together]). ***P < 0.001 versus empty vector. (E) LTC-IC assay 
of lentivirus infected cord blood CD34+ cells. CFC, colony-forming cell. The number of colony-forming cells after 5 weeks is also shown. Error bars 
indicate SEM of 3 independent experiments. (F) Competitive reconstituted mice were analyzed for 16 weeks for peripheral blood mononuclear 
cell donor/competitor ratios. CD45.2+ donors — with shRNA-mediated knockdown of murine (m-) L3mbtl1, Sgk2, L3mbtl1 and Sgk2 together, or 
scrambled control — were competed with equal numbers of CD45.1+CD45.2+ F1 competitors (n = 5) and injected into CD45.1+ hosts. 
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it was possible not only to induce expression of L3MBTL1 and 
SGK2, but also to recapitulate the reduced differentiation pheno-
type expected when the genes are expressed (Supplemental Figure 
6, G and H). To extend these results to primary cells, CD34+ cells 
from a patient with essential thrombocythemia and a 20q deletion 
(patient 13; Supplemental Table 2) were infected with retroviruses 
expressing L3MBTL1, SGK2, or both and grown as single-cell clones 
in conditions supporting erythroid differentiation. After 8 days, 
the presence of a 20q deletion was confirmed using microsatellite 
PCR, and GPA expression was assessed by FACS. As shown in Fig-
ure 6D, rescue of either L3MBTL1 or SGK2 expression resulted in a 
significant reduction in GPA levels, which were further reduced by 
combined expression of L3MBTL1 and SGK2. Together, these data 
were consistent with our knockdown results and demonstrated 
that L3MBTL1 and SGK2 cooperate to reverse the erythroid phe-
notype associated with 20q deletions.
Taken together, these data showed not only that L3MBTL1 
and SGK2 exhibit substantial interactions, but also that these 
interactions vary in different lineages and in successive stages 
of differentiation. In late megakaryocytic differentiation, loss of 
L3MBTL1 reverses the inhibitory effects of SGK2 loss, a dominant 
epistatic (or antagonistic) interaction. In contrast, the combined 
loss of L3MBTL1 and SGK2 has an additive positive effect on the 
proliferation of early erythroid progenitors, an observation con-
sistent with the BM erythroid hyperplasia associated with both 
MDS and MPN.
We considered the possibility that loss of L3MBTL1 and SGK2 
function may also provide a selective advantage at the level of 
HSCs or early progenitor cells. 3 different approaches were pur-
sued. First, lentiviral shRNA constructs were used to repress 
L3MBTL1 and/or SGK2 in human CD34+ progenitors, which 
were then assessed in long-term culture initiating cell (LTC-IC) 
assays. Inhibition of L3MBTL1 and/or SGK2 did not result in 
altered numbers of E-BFUs, GM-CFUs, granulocyte-erythrocyte-
monocyte-macrophage CFUs (GEMM-CFUs), or total colonies at 
the end of the LTC-IC culture period (Figure 6E and Supplemen-
tal Figure 6G). Second, lentiviral shRNA constructs were used to 
repress L3mbtl1 and/or Sgk2 in murine lineage-negative BM cells 
(Supplemental Figure 6H), which were then assessed in spleen 
CFU (S-CFU) assays. Inhibition of L3mbtl1 and/or Sgk2 did not 
result in alteration in the number or size of the S-CFUs (Supple-
mental Figure 6I and data not shown). Third, competitive BM 
transplantation experiments were performed. Lentivirally infect-
ed test BM cells (CD45.2+) were mixed with equal numbers of 
CD45.2+CD45.1+ (F1) competitor BM cells and transplanted into 
lethally irradiated CD45.1+ recipients. Knockdown of L3mbtl1 
and Sgk2 was sustained in lineage-negative CD45.2+ BM cells 16 
weeks after reconstitution (Supplemental Figure 6J). FACS analy-
sis 16 weeks after transplant showed that inhibition of L3mbtl1 
and/or Sgk2 did not alter the contribution of CD45.2+ test cells to 
peripheral blood (Figure 6F), to BM progenitor cells (Lin–Sca-1+ 
c-Kit–, common myeloid progenitor, granulocyte-macrophage 
progenitor, and megakaryocyte-erythroid progenitor; Supple-
mental Figure 6K), or to more mature cells positive for B220, 
CD71, Mac-1, or CD3ε (Supplemental Figure 6L). Together, 
these results indicate that inhibition of L3MBTL1 and/or SGK2 
does not result in a selective advantage for stem or early progeni-
tor cells and are consistent with previous evidence that several 
known driver mutations are not associated with an expanded 
HSC compartment (28, 41–47).
SGK2 and L3MBTL1 cooperate to regulate MYC transcription. 
To gain insight into the molecular basis for the cooperation 
between L3MBTL1 and SGK2, we focused on 3 known targets of 
L3MBTL1: MYC, RUNX1, and CCNE1 (15, 16). Transcript levels 
of all 3 genes were increased by repression of L3MBTL1 in ery-
throid cells generated by differentiation of cord blood progeni-
tors (Figure 7A). Repression of SGK2 did not alter expression of 
any of the 3 genes, but combined repression of both L3MBTL1 
and SGK2 gave rise to a striking increase in transcript levels of 
MYC, but not of RUNX1 or CCNE1 (Figure 7A and Supplemen-
tal Figure 7A). The synergistic increase in MYC expression was 
accompanied by similarly increased levels of H3K4me3 and RNA 
polymerase II at the MYC promoter and transcription start site, 
respectively (Figure 7B and Supplemental Figure 7, B and C), 
which indicates that L3MBTL1 and SGK2 cooperate by enhanc-
ing MYC transcription, rather than by altering MYC transcript 
stability. L3MBTL1 binding at the MYC promoter was reduced, 
as expected, by shRNA-mediated repression of L3MBTL1, but 
was not affected by repression of SGK2 alone, and no additional 
effect was obtained by repressing both L3MBTL1 and SGK2 (Fig-
ure 7C and Supplemental Figure 7C), which indicates that SGK2 
does not modulate MYC transcription by regulating the binding 
of L3MBTL1 to the MYC promoter.
We therefore searched for other mechanisms whereby SGK2 
might influence MYC transcription. Little is known about the 
biological functions of SGK2, but it has been shown that SGK 
family members are induced by MAPK signaling (48) and acti-
vated by the PI3K pathway (49). A potential link is provided 
by prior observations that MYC transcription is transiently 
upregulated by BRG1 (also known as SMARC4) (50), the ATPase 
subunit of a mammalian SWI/SNF-like chromatin remodel-
ing complex (51), and that serine phosphorylation of BRG1 
prevents its recruitment to DNA (52). We therefore tested the 
hypothesis that SGK2 might downregulate MYC transcription 
by inducing phosphorylation and inactivation of BRG1. Con-
sistent with this model, ChIP experiments demonstrated that 
repression of L3MBTL1 did not alter BRG1 binding to the MYC 
promoter. In contrast, repression of SGK2, either alone or in 
combination with repression of L3MBTL1, was accompanied by 
a marked increase in BRG1 recruitment (Figure 7D and Supple-
mental Figure 7E). Restoration of SGK2 expression in HNT-34 
cells, which carry a 20q deletion, was accompanied by increased 
levels of serine-phosphorylated BRG1, reduced binding of BRG1 
to the MYC promoter, and caused a concomitant decrease in 
MYC expression (Figure 7, E–G, and Supplemental Figure 7F). 
Furthermore, expression of L3MBTL1 and/or SGK2 was rescued 
in CD34+ cells a carrying 20q deletion that were derived from 
a patient with essential thrombocythemia (patient 13; Supple-
mental Table 2 and Figure 7H). Analyses of single-cell clones 
demonstrated that the 20q deletion clone generally expressed 
higher levels of MYC than WT clones, an effect that was partially 
reversed by expression of L3MBTL1 or SGK2 alone and complete-
ly reversed by their combined expression (Figure 7H).
Together, these results indicate that coordinate loss of expres-
sion of L3MBTL1 and SGK2, as a consequence of a 20q deletion, 
results in cooperative effects on distinct aspects of chromatin 
structure (Figure 7I). L3MBTL1 is known to regulate nucleosomal 
compaction, and we showed here that SGK2 inactivated BRG1, a 
key ATP-dependent helicase within the SWI/SNF complex that 
regulates nucleosomal positioning.
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Figure 7
Coordinated silencing of L3MBTL1 and SGK2 increases MYC transcription. (A) qPCR analysis of MYC, RUNX1, and CCNE1 transcript levels in 
cord blood–derived erythroid cells after lentiviral knockdown of L3MBTL1, SGK2, L3MBTL1 and SGK2 together, or scrambled shRNA control 
(n = 6). *P < 0.05, ***P < 0.001 versus scrambled control. (B–D) ChIP PCR analysis for binding of the indicated proteins at the MYC promoter 
(H3K4me3, L3MBTL1, and BRG1) or transcription start site (ph-S2-PolII) in erythroid cells infected with lentiviral shRNA as in A. Representative 
experiments are shown. Similar results were obtained in 2 further independent experiments (Supplemental Figure 7, B–E). Mean of duplicate 
qPCR measurements are shown. (E) Western blot from HNT-34 cells after immunoprecipitation with antibody against BRG1. Cells were trans-
fected with retroviral expression constructs as indicated. (F and G) HNT-34 cells infected with retrovirus expressing SGK2 or control and analyzed 
for binding of BRG1 (as described above) to the MYC promoter (F) or MYC transcript levels (G). *P < 0.05 versus control. (H) Expression of MYC 
(qPCR) in single-cell clones grown in erythroid conditions. CD34+ cells from patient 13 were infected with retroviruses expressing L3MBTL1 and/
or SGK2 as indicated. Each data point represents 1 clone; horizontal lines denote means. n = 10 in each case. ***P < 0.001 versus empty vec-
tor–containing 20q deletion clones. (I) Collaboration between L3MBTL1 and SGK2.
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patients in whom at least 98% of cells carried the deletion; for 
colony assays, we were limited to those samples from which it was 
possible to grow adequate numbers of colonies (a particular prob-
lem in MDS) carrying an unambiguous deletion. The latter was 
assessed using multiple microsatellite markers to avoid artifacts 
that can result from preferential amplification of smaller alleles, 
especially when starting from small amounts of low–molecular 
weight DNA. Moreover, we found that individual hematopoietic 
colonies were often contaminated by background cells (e.g., mac-
rophages and platelets) present in the methylcellulose; to reduce 
this, we introduced a CD34 selection step prior to seeding cells 
into methylcellulose.
It is instructive to compare our results with previous studies 
of L3MBTL1 expression in hematopoietic cells with and without 
a 20q deletion. MacGrogan and colleagues reported detectable 
expression of L3MBTL1 in some, but not all, cell lines with 20q 
LOH and in 15 AML samples, none of which had a 20q deletion 
(23). However, LOH in cell lines with complex genomic rearrange-
ments may not reflect the same pathogenetic mechanisms as a 
simple cytogenetically detectable 20q deletion in patient samples; 
for this reason, our mapping of the CDR was restricted to sam-
ples from MPN or MDS patients (11–13). It has been reported 
that L3MBTL1 transcript levels in peripheral blood granulocytes, 
detected using primers from the 3′ region of the L3MBTL1 locus, 
were not affected by the presence of a 20q deletion (13). How-
ever, the conclusions of this study were limited by several caveats, 
including the complex transcriptional architecture of the locus 
with the possibility that a subset of transcripts might not be 
imprinted, and the issue of contaminating normal undeleted cells 
(up to 10% of cells did not carry a 20q deletion). This problem 
was compounded by the fact that normal granulocyte expression 
levels varied considerably between individuals (∼6-fold). In the 
current study, we demonstrated that multiple different L3MBTL1 
transcripts were lost in association with 20q deletions, which 
indicates that imprinting affects all known L3MBTL1 transcripts. 
Here, we took great care to minimize contamination by nonde-
leted cells in our studies of peripheral blood granulocytes and 
hematopoietic colonies. Importantly, our data also demonstrated 
the presence of an antisense transcript overlapping the 3′ region 
of the L3MBTL1 locus, with low-level expression from the retained 
allele potentially masking loss of expression of sense transcripts 
when using primers from the 3′ region (13).
Targeted inactivation of SGK2 has not been reported, but mice 
lacking L3MBTL1 do not exhibit a detectable hematopoietic phe-
notype (57). This observation is likely to reflect a requirement 
for loss of L3MBTL1 activity to cooperate with additional lesions, 
such as loss of SGK2 expression. In MPN patients, the absence of 
microdeletions affecting L3MBTL1 and SGK2 (58) argues that loss 
of additional genes (on 20q, but outside the CDR) may well be 
required, a scenario reminiscent of prior data implicating several 
different genes in the pathogenesis of 5q deletions associated with 
MDS (7–9, 59). Moreover, our results do not exclude a further 
requirement for cooperation between 20q deletions and lesions 
elsewhere in the genome.
Since myeloid malignancies associated with 20q deletions gener-
ally occur in elderly individuals, parental samples are not available 
to ascertain the parental origin of the retained allele. We instead 
assessed the methylation status of patients with 20q deletions that 
lacked L3MBTL1 expression in their granulocytes (Figure 4E and 
ref. 24). The retained L3MBTL1 allele was methylated as expected 
Discussion
Our data provided a pathogenetic link between an acquired 
cancer-associated genetic lesion and an imprinted gene cluster. 
Moreover, they revealed a new tumorigenic mechanism associat-
ed with acquired chromosome deletions. Some somatic deletions 
remove the remaining normal allele of a heterozygously inacti-
vated tumor suppressor gene (e.g., TP53, RB, and p16, refs. 53–
55), whereas others result in haploinsufficiency (e.g., α-catenin, 
RPS14, and miR-145 and miR-146a; refs. 7–9). Here, we identified a 
third mechanism in which a deletion removes actively expressed 
alleles of an imprinted gene cluster, resulting in the coordinate 
and complete loss of expression of several genes. Importantly, the 
3 mechanisms are not mutually exclusive, and our data do not 
exclude an additional pathogenetic role for other genes on 20q. 
Our results have relevance extending well beyond the specific 
example of 20q deletions. Monoallelic or allelically imbalanced 
transcription can reflect processes other than imprinting (e.g., 
regulatory element polymorphisms), and it has also been report-
ed that monoallelic expression is much more widespread than 
previously recognized (56). These considerations raise the possi-
bility that the mechanism described here (marked loss of expres-
sion of multiple genes) may also be a feature of other examples of 
malignancy-associated, acquired, large-scale genetic loss, includ-
ing other deletions and monosomies as well as regions of unipa-
rental disomy.
We have previously shown that L3MBTL1 is imprinted (24), 
and here we describe that it is part of a previously unrecognized 
imprinted gene cluster that arose in the primate line after its 
divergence from other placental mammals. L3MBTL1, SGK2, and 
GDAP1L1 were expressed from the paternally derived allele, which 
suggests a common regulatory mechanism. We also identified a 
promoter of L3MBTL1 as a germline DMR, unmethylated in sperm 
but methylated in oocytes, and therefore a strong candidate for the 
imprinting control region. Deletions of chromosome 20q result-
ed in markedly reduced expression of L3MBTL1 and SGK2, which 
indicates that monoallelic expression of L3MBTL1 and SGK2 is 
tightly regulated, perhaps reflecting the proximity of both to the 
DMR. In contrast, loss of expression of GDAP1L1, located approxi-
mately 800 kb away from the other 2 genes, was observed in some, 
but not all, individuals with a 20q deletion. This is consistent with 
the idea that the influence of the DMR becomes attenuated over 
large distances, but our data do not exclude the possibility that 
GDAP1L1 is independently regulated, perhaps in a lineage-restrict-
ed or disease-associated manner. Of particular note, monoallelic 
expression of all 3 genes was a recent evolutionary development; 
to our knowledge, this represents the first example of primate-
restricted imprinting.
Our data demonstrated that acquired deletions of 20q were 
associated with consistent loss of the active alleles of L3MBTL1 
and SGK2. For L3MBTL1, this pattern was observed in all 16 sam-
ples studied, patients 1–14 (Supplemental Table 2) together with 
cell lines HNT-34 and UKE-1, and our results therefore indicate 
a pathogenetic role for loss of the paternally derived active locus. 
Our results do not reflect bias in the selection of samples for 
analysis. Although we were able to study a minority of patients 
with a 20q deletion, patient selection was determined solely by 
the technical challenges associated with detecting loss of expres-
sion in a clonal subpopulation of deleted cells present in a mixed 
population containing nondeleted cells. Studies of peripheral 
blood granulocytes were therefore restricted to the minority of 
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to the MYC promoter. Coordinated repression of both L3MBTL1 
and SGK2 resulted in a synergistic increase in MYC expression as a 
consequence of cooperation between the distinct chromatin-mod-
ifying activities of L3MBTL1 and the SWI/SNF complex. L3MBTL1 
recognizes H4K20me1 and H1bK26me1/2 and compacts chroma-
tin, either by acting as a molecular bridge between adjacent nucleo-
somes or by binding to an individual nucleosome and altering 
internucleosomal interactions (16). In contrast, SWI/SNF com-
plexes regulate gene expression by inducing nucleosomal repo-
sitioning that alters accessibility of regulatory DNA to the tran-
scriptional machinery (64). The model in Figure 7I is consistent 
with the antagonistic effect of polycomb group proteins and SWI/
SNF complexes (64, 65) and has parallels with the observation 
that a lymphoma-associated amplicon contains 2 genes, JAK2 and 
JMJD2C, increased expression of which cooperates to promote lym-
phoma development (66). Moreover, our results are also in accord 
with the demonstration that downregulation of MYC is essential 
for eythroid differentiation and that a 2- to 3-fold increase in MYC 
expression promotes proliferation of early erythroblasts (67). The 
coordinate regulation of gene dosage by genomic imprinting at 
closely linked genes functioning in distinct molecular pathways 
aberrant in hematological malignancy has important evolution-
ary implications for our understanding of the effect of epigenetic 
control on disease development. Together, our data revealed previ-
ously unrecognized biological links between the epigenetic regula-
tor L3MBTL1 and the little-studied serine/threonine kinase SGK2 
and underlined the complex molecular and cellular consequences 
of “simple” cancer-associated chromosome deletions.
Methods
Patient samples. See Supplemental Methods.
Hematopoietic colony assays. Peripheral blood mononuclear cells from nor-
mal individuals and CD34+ cells from 20q deletion patients were isolated 
as described above. Cells were grown at a density of 1–5 × 104 cells/ml in 
H4034 methylcellulose medium (Stem Cell Technologies) for 14–21 days 
according to the manufacturers’ instructions. Individual E-BFUs or GM-
CFUs were picked by aspiration and directly added to 50 μl RLT buffer. 
DNA and RNA were isolated as described below.
FISH. See Supplemental Methods.
Differentiation of CD34+ cord blood cells. Cord blood was collected from 
consenting mothers undergoing elective cesarean section surgery in the 
Rosie maternity Hospital (Cambridge, United Kingdom). CD34+ cells were 
isolated (see Supplemental Methods), then cultured in serum-free media 
as described previously (68). Briefly, 200,000 CD34+ cells were cultured in 
StemSpan (Stem Cell Technologies) and 1% penicillin/streptomycin plus 1 
U/ml Epo (NeoRecormon), 25 ng/ml SCF (Peprotech), 10 μM/ml 2-mercep-
toethanol, 0.1% BSA, 4 μg/ml dexamethasone, and 300 μg/ml holo-trans-
ferin (iron saturated) for erythroid differentiation, or 100 ng/ml Tpo (Pep-
rotech) and 10 ng/ml IL-1β (Peprotech) for megakaryocytic differentiation.
Biphasic erythroid differentiation assay. See Supplemental Methods.
LTC-IC assay. See Supplemental Methods.
Single-cell clonality assay. See Supplemental Methods.
Cell culture of cell lines. See Supplemental Methods.
shRNA generation and viral infection. See Supplemental Methods.
Retrovirus generation and transduction. See Supplemental Methods.
Hemin-induced erythroid differentiation assay. HNT-34 cells were infected 
with retroviruses expressing L3MBTL1-GFP, SGK2-CFP, or both con-
structs together or empty vector using the following method. Viral super-
natant was diluted with fresh RPMI supplemented with 10% heat-inacti-
vated FCS and 1% penicillin/streptomycin and used for infecting cells in 
in most patients, but was unmethylated in patient 5. Analysis of 
NNAT methylation was consistent with retention of the maternal 
chromosome in this and all other tested patients that harbored 
20q deletions. This suggests the retained L3MBTL1 allele has 
undergone aberrant hypomethylation, a phenomenon well estab-
lished in multiple malignancies (60). Our results do not exclude 
the possibility that in a minority of patients, the active paternal 
allele was retained, and that other acquired genetic or epigenetic 
mechanisms explain the coordinate loss of expression of L3MBTL1 
and SGK2. Such mechanisms may account for the previous report 
of a patient harboring 2 20q deletions in distinct clones and affect-
ing the maternal and paternal chromosomes (61). Alternatively, 
rare 20q deletions affecting the repressed maternal allele may be 
associated with different molecular lesions, such as haploinsuf-
ficiency for, or mutation of, other target genes on 20q, perhaps in 
concert with distinct lesions elsewhere in the genome.
Loss of L3MBTL1 and/or SGK2 did not result in an advantage 
for early stem or progenitor cells, as assessed by LTC-IC, S-CFU, 
or competitive BM transplantation studies. These results were 
consistent with previous reports showing that several driver muta-
tions found in human myeloid malignancies — including BCR-ABL 
(46, 47), RUNX1 inactivation (42), NRAS activation (45), FLT3-ITD 
(43), and JAK2V617F (28, 41, 44) — are not associated with a selec-
tive advantage in the HSC compartment and may even impair the 
function of early stem and progenitor cells. These observations may 
be related to oncogene-induced senescence, a phenomenon most 
studied in solid tumors, but also triggered by leukemogenic fusion 
proteins (62), and suggest that additional lesions are required for 
the progeny of a mutated HSC to acquire a clonal advantage.
In chronic myeloid malignancies, the clinical phenotype reflects 
perturbation of late stages of hematopoiesis. Thus, in the chron-
ic phase of disease, BCR-ABL and JAK2V617F are associated with 
increased granulopoiesis and erythropoiesis, respectively (41, 44, 
47). We showed here that coordinate loss of expression of L3MB-
TL1 and SGK2, as a consequence of a single heterozygous deletion, 
gave rise to dysregulation of erythropoiesis and megakaryopoi-
esis. Perna and colleagues previously reported that repression of 
L3MBTL1 alone increases erythroid differentiation of CD34+ cells, 
although they did not detect altered megakaryocyte differentia-
tion (63), perhaps reflecting differences in the cytokine combina-
tion used. Here, we demonstrated that repression of L3MBTL1 and 
SGK2 cooperated to dysregulate both erythropoiesis and mega-
karyopoiesis. Furthermore, our data demonstrated that L3MBTL1 
and SGK2 interacted in distinct ways, depending on cellular con-
text. In megakaryocytic differentiation, repression of L3MBTL1 
compensated for the inhibitory effects of SGK2 loss. In contrast, 
proliferation of early erythroid progenitors was enhanced coopera-
tively by repression of both L3MBTL1 and SGK2. Our results there-
fore identified L3MBTL1 and SGK2 as potential therapeutic tar-
gets; however, future approaches will need to take into account the 
fact that increasing L3MBTL1 activity alone would be predicted to 
unmask the detrimental effect of SGK2 loss on megakaryopoiesis.
Finally, we demonstrated that L3MBTL1 and SGK2 collaborate 
during erythropoiesis in the epigenetic regulation of MYC, but 
not other known human L3MBTL1 target genes. Repression of 
L3MBTL1 has been shown to relax nucleosomal compaction and 
is associated with increased MYC expression in cell lines (16). 
Here, we showed that SGK2 regulated phosphorylation of BRG1, 
a critical ATPase subunit of mammalian SWI/SNF-like chromatin 
remodeling complexes (51, 64), and modulated BRG1 recruitment 
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tion and CD2 selection was performed using immunomagnetic beads 
following the manufacturer’s instructions (Dynabeads; Invitrogen), and 
CD34 and GPA selection was performed using immunomagnetic beads 
following the manufacturer’s instructions (Miltenyi Biotech). Erythroid 
cells were prepared using the single-phase erythroid differentiation sys-
tem, beginning with the peripheral blood buffy coat mononuclear cell step. 
Cells were analyzed by FACS on day 8 to show that all GPA+ cells were also 
CD71+, after which GPA+ cells were isolated by magnetic separation. See 
Supplemental Methods for primer sequences.
Colony genotyping. See Supplemental Methods.
Strand-specific cDNA synthesis and PCR. See Supplemental Methods.
ChIP. See Supplemental Methods.
Immunoprecipitation and Western blot. See Supplemental Methods.
Flow cytometry antibodies. CD61–Alexa Fluor 647 (clone VI-PL2) was 
obtained from Biolegend; all other antibodies were from Invitrogen (Clon-
tech): CD71-APC (clone T56/14), GPA-PE (clone AME-1), CD34–PE-Cy5.5 
(clone 581[class III]), and CD41-PE (clone VIPL3). All anti-mouse FACS 
antibodies were obtained from BD Biosciences — Pharmingen and were 
described previously (44).
Statistics. Unpaired 2-tailed Student’s t test was used for all analyses, using 
Prism software (version 4; GraphPad). A P value less than 0.05 was consid-
ered significant.
Study approval. Studies using human samples were approved by the 
Cambridge and Eastern Region Ethics Committee (REC; reference no. 
07/MRE05/44). Patients gave written informed consent, and research 
was carried out in accordance with the Declaration of Helsinki. Studies 
using macaques were approved by the SingHealth IACUC (approval no. 
2009/SHS/509). Studies using mice were approved by the UK home office 
(license nos. 80/2376 and 80/2567). Studies using tammar wallabies were 
approved by institutional ethics committees at the University of Mel-
bourne (specimen transfer agreement reference no. GB107A).
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6-well fibronectin-coated plates. 2 rounds of spin infections were carried 
out within 12 hours using 1,139 g at 32°C. Medium was changed after 
12 hours of infection, and cells were induced with 50 μM hemin in RMPI 
supplemented with 10% heat-inactivated FCS and 1% penicillin/streptomy-
cin. Cell counts and FACS analysis for surface GPA was performed every 24 
hours starting 48 hours after infection. RNA was extracted at day 4 of cul-
ture for globin gene expression analysis. HNT-34 cells were induced toward 
the erythroid lineage with hemin (50 μM), and at the same time, 5-azacyti-
dine was added to the medium (0, 200, or 500 nM) to induce expression of 
the imprinted genes. HNT-34 cells were analyzed for GPA expression 3 days 
after induction, and RNA was extracted for analysis of gene expression.
RNA extraction and cDNA synthesis. Cell fractions from patients were lysed 
in RLT buffer for extraction using the RNeasy kit (Qiagen). Individual 
patient colonies and clones were picked into 50 μl RLT buffer, RNA extrac-
tions were performed on 30 μl of the lysates using either the RNeasy kit 
or the PicoPure RNA extraction kit (Arcturus), both according to the 
manufacturer’s instructions, with an additional final spin of the columns 
while empty before elution. cDNA synthesis was performed as described 
previously (24). For tammar wallabies, cDNA was generated using random 
hexamers or oligo dT using Fermentas RevertAid H minus First Strand 
cDNA Kit. For macaques, cDNA was obtained by RNA extraction using the 
Qiagen RNeasy kit followed by DNase I treatment and random hexamer 
reverse transcription as above.
Tammar wallaby SNP genotyping. The sequence for the tammar wallaby 
was inferred from the South American short-tailed opossum and con-
firmed by sequencing the entire L3MBTL1 gene to identify an expressed 
C/T SNP in 4 animals; no other SNPs were found. See Supplemental Meth-
ods for SNP primer sequences.
Macaque SNP genotyping. L3MBTL1 and SGK2 were analyzed in 4 animals 
(2 male and 2 female) and were found to be informative for at least 3 SNPs 
in each gene. SNPs at chr10 (–) 20910951 (L3MBTL1) and 20867268 (SGK2) 
were used for further analysis.
Human SNP genotyping for expressed alleles. See Supplemental Methods.
Mutation and sequencing analysis. See Supplemental Methods.
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